Condition: Advanced High-Grade Epithelial Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancers · Sponsor: AbbVie
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FRα). Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). There are 2 cohorts in this study, the Randomized Phase 2 Cohort and the Hepatic Impairment Cohort. In the Randomized Phase 2 Cohort, participants are placed in 1 of 2 groups, called treatment arms. Each treatment arm receives MIRV on a different schedule (on day 1 every 21 days or on days 1 and 15 every 28 days). The Hepatic Impairment Cohort is designed to determine the starting dose of MIRV in patients with moderately abnormal liver function. Around 110 participants will be enrolled in the study at approximately 75 sites worldwide. The total study duration will be approximately 24 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may r…
This description comes directly from the study's public registry record.
ABBVIE CALL CENTER · 844-663-3742 · abbvieclinicaltrials@abbvie.com
Always discuss trial participation with your own doctor first.
| First Physicians Group /ID# 272180 | Sarasota, Florida, United States | Recruiting |
| St. Elizabeth Medical Center - Edgewood /ID# 272113 | Edgewood, Kentucky, United States | Recruiting |
| Baptist Health Lexington /ID# 272211 | Lexington, Kentucky, United States | Recruiting |
| UMass Memorial Medical Center - Belmont Street /ID# 272122 | Worcester, Massachusetts, United States | Recruiting |
| Karmanos Cancer Institute - Detroit /ID# 272112 | Detroit, Michigan, United States | Recruiting |
| Allegheny Health Network West Penn Hospital /ID# 272267 | Pittsburgh, Pennsylvania, United States | Recruiting |
| Memorial Hermann Texas Medical Center /ID# 272227 | Houston, Texas, United States | Recruiting |
| Blacktown Hospital /ID# 272182 | Blacktown, New South Wales, Australia | Recruiting |
| Newcastle Private Hosptial /ID# 272213 | Lambton Heights, New South Wales, Australia | Recruiting |
| Royal Brisbane and Women's Hospital /ID# 272123 | Brisbane, Queensland, Australia | Recruiting |
| Icon Cancer Centre Chermside /ID# 272220 | Chermside, Queensland, Australia | Recruiting |
| Ballarat Base Hospital /ID# 272240 | Ballarat, Victoria, Australia | Recruiting |
+ 40 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06682988